Trials / No Longer Available
No Longer AvailableNCT03914872
Expanded Access Neoantigen Vaccine in Solid Tumors
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Washington University School of Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access use study. Safety data will be collected from participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Neoantigen DNA Vaccine | The schedule for vaccination will be weeks 1, 5, 9, 13, 17, and 21. All vaccines will occur within +/- 1 week with at least 3 weeks between vaccines. |
| DEVICE | Integrated electroporation device | * Ichor Medical Systems * All study injections will be given intramuscularly using an integrated electroporation device |
Timeline
- First posted
- 2019-04-16
- Last updated
- 2024-03-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03914872. Inclusion in this directory is not an endorsement.